Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Revenues for ERIS are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.741000
forwardPE 21.823092
debtToEquity 60.545000
earningsGrowth 2.000000
revenueGrowth 0.071000
grossMargins 0.744580
operatingMargins 0.271170
trailingEps 45.210000
forwardEps 62.383460

ERIS's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
ERIS's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
ERIS's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that ERIS is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for ERIS
Price projections for ERIS

Eris Lifesciences Limited's current price does not reveal any distinct risks or opportunities compared to its projections. This neutral assessment suggests stability, where investors might choose to retain their current positions until future developments warrant a reassessment.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


A recent buy bias from analysts toward ERIS indicates strong confidence in the stock's future performance. This could encourage investors to park their money in ERIS, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.